Search

Peptides can affect the recognition of MHC class I molecules by allospecific antibodies. Two explanations have been proposed for this phenomenon. The 'conformational change' hypothesis suggests that peptide binding affects the availability of serologic determinants in the class I alpha1 and alpha2 domains while the 'peptide-side-chain effect' predicts that solvent exposed residues in the peptide are part of the serologic epitope. We have tested these possibilities by examining the recognition of peptide loaded HLA A*1101 molecules expressed in transporters associated with antigen processing (TAP)-deficient cell lines by three A11-specific mAb, and by comparing the effect of peptide analogues on the recognition of A11 complexes containing peptide epitopes from the Epstein-Barr virus nuclear antigen EBNA4 by antibodies and cytotoxic T lymphocytes (CT). The AUF5.13 and HB164 antibodies showed selective recognition of A11 molecules bound to partially overlapping sets of peptides from viral or cellular origin. The peptide dependence of AUF5.13 was confirmed in reconstitution experiments where A11 molecules were refolded at the surface of TAP-deficient T2/A11 cells that had been cultured at 26 degrees C and treated at pH3. Molecular modelling and Ala scanning mutagenesis of the IVTDFSVIK (IVT) and AVFDRKSDAK (AVF) peptides demonstrated that solvent-exposed peptide side chains affect CTL recognition as well as antibody binding. Substitution of Phe-P5 or Ser-P6 of the IVT peptide with Arg or Lys inhibited AUF5.13 recognition while binding was induced by substitution of the Arg-P5 and Lys-P6 of the AVF peptide with Ala. The results suggest that some allospecific antibodies recognized the surface of MHC class I-peptide complexes in a fashion similar to the TCR. This may involve direct interaction with the peptide side chains as well as recognition of peptide-induced perturbations in the class I complex.

Human blood lymphocytes were fractionated on the basis of surface characteristics such as adherence to nylon wool and expression of erythrocyte (E) and Fc receptors. The various subsets were incubated with interferon for 3 hr. Two cell lines that differ in sensitivity to the natural killer effect, K562 and Daudi, were exposed to these lymphocytes (i.e., their sensitivity to interferon-activated killing was tested.) Cell line Daudi, with a low sensitivity to the natural killer effect, was also affected by interferon-activated killing. The efficiency of the nonadherent subsets, separated according to the expression E receptor, ranked similarly in natural killing (anti-K562) and interferon-activated killing (anti-K562 and anti-Daudi) in the following order: E receptor-negative cells, low-affinity E receptor-positive cells, and high-affinity E receptor-positive cells. Further separation on the basis of Fc receptor expression revealed a difference between the two targets. The Fc receptor-positive and -negative cells that did not express high-affinity E receptors killed K562 with similar efficiency whereas Daudi cells were more sensitive to the effect of cells devoid of Fc receptor. Results obtained with other targets suggested that T cell lines behave similarly to K562 and that the difference may be generally valid for T and B cell lines.

Nonproductive infection of B lymphocytes by Epstein-Barr virus (EBV) is associated with a highly restricted expression of viral genes. In growth-transformed lymphoblastoid cell lines, the products of these genes include a complex of at least six EBV nuclear antigens (EBNAs) (EBNA-1 through EBNA-6) and one membrane protein (latent membrane protein [LMP]). EBV-carrying Burkitt's lymphoma (BL) biopsies and derived cell lines that have retained a representative phenotype (group I BL lines) express only EBNA-1 (M. Rowe, D. T. Rowe, C. D. Gregory, L. S. Young, P. J. Farrell, H. Rupani, and A. B. Rickinson, EMBO J. 6:2743-2751, 1987). We have found that EBNA-2 through EBNA-6 and LMP can be up regulated by treating the group I BL line Rael with the DNA-demethylating agent 5-azacytidine (5-AzaC). The drug acted in a time- and dose-dependent manner. EBNA-2-positive cells were detected by anti-complement immunofluorescence staining just 12 h after addition of 4 microM 5-AzaC and reached a maximum number at 72 h, when up to 75% of the population was positive. EBNA-2, EBNA-3, EBNA-4, EBNA-4, EBNA-6, and LMP were demonstrated immunoblots starting at 48 h. The EBV-encoded early antigens and viral capsid antigens were also induced but at a lower level. EBNA-2 and the lytic cycle-associated antigens appeared with a different time course and in largely nonoverlapping cell subpopulations, as demonstrated by double fluorescence staining. Thus, EBNA-2 expression was not restricted to lytically infected cells, nor was EBNA-2 required for entry into the lytic cycle. The coding and regulatory sequences of EBNA-2 and LMP were found to be highly methylated in Rael cells and were, as expected, demethylated after 5-AzaC treatment. These findings suggest that DNA methylation may participate in the regulation of growth transformation-associated viral genes in BL cells.

We have analyzed the expression of the three major known growth transformation-associated Epstein-Barr virus (EBV) proteins, EBNA-1, EBNA-2, and latent membrane protein (LMP), in a series of somatic cell hybrids derived from the fusion of EBV-carrying Burkitt lymphoma (BL) lines with EBV-positive or EBV-negative B-cell lines. Independently of the cell phenotype, EBNA-1 was invariably coexpressed in all EBV-carrying hybrids. In hybrids between EBV-carrying, LMP-positive and LMP-negative Burkitt lymphoma lines, LMP was expressed, indicating positive control. Two EBV-negative lymphoma lines, Ramos and BJAB, differed in their ability to express LMP after B95-8 virus-induced conversion and after hybridization with Raji cells. BJAB was permissive while Ramos was nonpermissive for LMP, although both expressed EBNA-2. The EBNA-2-deleted P3HR-1 virus gave the same pattern of LMP expression in these two cells. Our findings indicate that the expression of EBNA-1, EBNA-2, and LMP is regulated by independent mechanisms.

Blood lymphocytes from tumor patients were cocultivated with allogeneic lymphocytes (MLC) or autologous tumor cells (ATS), and their cytotoxicity was characterized. The main objective of the study was the lysis of autologous tumor biopsy cells by such effectors. Lymphocytes of patients activated in MLC lysed allogeneic third-party cells and in some cases also lysed autologous tumor cells. Allogeneic but not autologous PHA blasts were also damaged by these effectors. The cytotoxic potential of MLC-activated lymphocytes from healthy donors was similar; allogeneic tumors and phytohemagglutinin (PHA) blasts but not autologous PHA blasts were lysed. The cytotoxicity of lymphocytes activated in ATS were specific for the stimulator because they acted only on the autologous tumor cells. Allogeneic tumors and autologous and allogeneic PHA blasts were not lysed. The pattern of cytotoxicity with regard to this target panel was maintained when the MLC or ATS cultures were further propagated with TCGF. Results obtained in cold target competition assays suggested (a) activated lymphocyte lyse the third party tumor targets because of alloantigen recognition; (b) in MLC several different sets of alloreactive cytotoxic lymphocytes are present simultaneously; and (c) the alloreactive cells are different than those that act on the autologous tumor cells. Thus, the lysis of allogeneic tumor cells by lymphocytes of the patient is not due to recognition of cross-reacting tumor-related antigens, and the autotumor cytotoxicity of the patients' MLC-activated lymphocytes if performed by specifically reacting cells.